Skip to Main Content

Paper Details

Efficacy and safety of Ixekizumab vs. low-dose IL-2 vs. Colchicine vs. standard of care in the treatment of patients hospitalized with moderate-to-critical COVID-19: A pilot randomized clinical trial (STRUCK: Survival Trial Using Cytokine Inhibitors).
Rev Soc Bras Med Trop
4
2023
Author NameAffiliation
Renato D LopesBrazilian Clinical Research Institute
Renato D LopesDuke University Medical Center - Duke Clinical Research Institute
  • 1 - 2

Datasets

Release 1.2